What was the rationale for adding zanubrutinib to mosunetuzumab in the MITHIC-FL2 trial?
To increase the production of CD20-positive B cells
To mitigate or reverse T cell exhaustion observed after mosunetuzumab administration
To reduce the duration of treatment required